Acadia Pharmaceuticals (ACAD) Short-term Investments (2010 - 2026)

Acadia Pharmaceuticals' Short-term Investments history runs 17 years deep, the most recent figure standing at $569.2 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 22.71% year-over-year to $569.2 million; the TTM figure through Mar 2026 stood at $569.2 million (up 22.71% YoY), while the FY2025 annual figure was $642.0 million, up 47.11% from the prior year.
• Short-term Investments for Q1 2026 stood at $569.2 million, down from $642.0 million in the prior quarter.
• The five-year high for Short-term Investments was $642.0 million in Q4 2025, with the low at $112.0 million in Q1 2023.
• The 5-year median for Short-term Investments is $302.0 million (2022), against an average of $365.1 million.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments tumbled 53.55% in 2023, then surged 137.35% in 2024.
• Acadia Pharmaceuticals' Short-term Investments stood at $302.0 million in 2022, then retreated by 17.14% to $250.2 million in 2023, then soared by 74.42% to $436.4 million in 2024, then surged by 47.11% to $642.0 million in 2025, then slipped by 11.33% to $569.2 million in 2026.
• Business Quant data shows ACAD's Short-term Investments at $569.2 million in Q1 2026, $642.0 million in Q4 2025, and $589.0 million in Q3 2025.